Illustrative trial dosing schedule (for educational reference only sourced from the NEJM 2023 Phase 2 trial
For GLP-1 users, reduced appetite and altered thirst signals can make fluid intake harder to maintain, particularly in hot conditions
NP reports participating in advisory boards for Britannia, Boston Scientific, Benevolent AI, Hoffmann-La Roche, Inc., and Abbvie
Recommended Stage 2 Tech Stack Questions to consider at Stage 2 Are your marketing claims defensible
FDA-Approved Semaglutide Pathways Wegovy Injection (Semaglutide 2.4 mg Weekly) According to FDA prescribing information, Wegovy injection is indicated to reduce excess body weight and maintain weight reduction in adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related condition, used alongside reduced-calorie diet and increased physical activity
Fortunately, recent advancements in weight management offer a glimmer of hope